CARIS SCIENCE, INC.

ADAPT

Healthcare services, namely, analysis of individual patient RNA, DNA and protein for diagnosis of disease and prognosis of the expected progression of the disease and to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients; Healthcare services, namely, an analytic platform for identification of molecular targets for diagnosis, prognosis, and therapeutics;

ADAPT BIOTARGETING

Healthcare services, namely, analysis of individual patient RNA, DNA and protein for diagnosis of disease and prognosis of the expected progression of the disease, and to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients;BIOTARGETING;Medical and scientific research and analysis services in the field of molecular biology, namely, identification of molecular targets for diagnosis, prognosis, and therapeutics in the field of healthcare;

ADAPTAMERS

Nucleic acid molecules for medical purposes;

ADAPTAMERS

Medical and scientific research and analysis services in the field of molecular biology, namely, identification of molecular targets for diagnosis, prognosis, and therapeutics in the field of healthcare; Medical and scientific research and analysis services in the field of molecular biology through use of nucleic acid molecules to identify molecular targets for diagnosis, prognosis, and therapeutics in the field of healthcare;

CARIS

medical diagnostic, theranostic, prognostic and analysis services, namely, pathology diagnostic services;

CARIS

Medical research; medical and scientific research services in the fields of anatomic pathology, molecular profiling, blood-based diagnostics, oncology, genomics, and proteomics; pharmaceutical research and development; genetic and proteomic research studies of specimens; genetic and proteomic research studies of specimens, namely, cellular manipulation, light microscopic examination, immunohistochemistry flow cytometry, expression profiling, microarray analysis, genetic signatures, specific genetic targets, DNA/RNA isolation and western blot analysis, facilitating effective clinical trials, product development, and research using large amounts of biospecimens and associated research and patient data; providing temporary use of nondownloadable software for tracking laboratory information featuring customized biospecimens and coordinating and conducting follow-on studies to complement the clinical findings; medical and scientific research; providing medical and scientific research in the fields of oncology, and molecular profiling, genomics and proteomics; conducting clinical trials; medical services, namely, analysis of individualized patient data to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients; medical services, namely, providing patient history reports based on analysis of RNA, DNA and protein to aid physicians in determining diagnosis, prognosis, and predicting or monitoring therapeutic response for cancer patients; health care services, namely, providing a centralized database in the field of molecular diagnostics to allow oncologists to acquire and share molecular tumor profiling information and clinical outcomes within a collaborative, secured environment, all for treatment and diagnostic purposes;

CARIS

CAR IS;Medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services in the field of cancer; prognostic analysis services for medical purposes; theranostic analysis services for medical purposes; molecular diagnostic services for medical purposes;

CARIS LIFE SCIENCES

The mark consists of the wording CARIS LIFE SCIENCES in stylized font underneath three arched, half-concentric, curved lines. The wording CARIS is over the wording LIFE SCIENCES.;Color is not claimed as a feature of the mark.;medical screening services; medical diagnostic testing, monitoring and reporting services; pathology diagnostic services; prognostic analysis services; theranostic analysis services;LIFE SCIENCES;